| Title |
RASopathic Skin Eruptions during Vemurafenib Therapy
|
|---|---|
| Published in |
PLOS ONE, March 2013
|
| DOI | 10.1371/journal.pone.0058721 |
| Pubmed ID | |
| Authors |
Jeannine D. Rinderknecht, Simone M. Goldinger, Sima Rozati, Jivko Kamarashev, Katrin Kerl, Lars E. French, Reinhard Dummer, Benedetta Belloni |
| Abstract |
Vemurafenib is a potent inhibitor of V600 mutant BRAF with significant impact on progression-free and overall survival in advanced melanoma. Cutaneous side effects are frequent. This single-center observational study investigates clinical and histological features of these class-specific cutaneous adverse reactions. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 48 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 2% |
| Hungary | 1 | 2% |
| Portugal | 1 | 2% |
| Unknown | 45 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 21% |
| Other | 6 | 13% |
| Student > Bachelor | 4 | 8% |
| Student > Doctoral Student | 3 | 6% |
| Student > Ph. D. Student | 3 | 6% |
| Other | 8 | 17% |
| Unknown | 14 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 26 | 54% |
| Agricultural and Biological Sciences | 3 | 6% |
| Social Sciences | 2 | 4% |
| Immunology and Microbiology | 1 | 2% |
| Psychology | 1 | 2% |
| Other | 0 | 0% |
| Unknown | 15 | 31% |